Relay Therapeutics, Inc.
No SEC Form 4 filings for $RLAY in the last 30 days.
Relay Therapeutics has announced a public stock offering aiming to raise $175 million. The biotechnology company is looking to secure additional capital through this offering to support its operations and research efforts.
Relay Therapeutics Inc is expected to report an earnings loss of 38 cents per share, according to a preview from Refinitiv. The article provides this key financial expectation for the company.
Relay Therapeutics executive Peter Rahmer sold 753 shares of common stock at $14.79 per share. This non-discretionary sale was solely to cover income tax withholding obligations from the vesting of 3,051 restricted stock units. After the transaction, Rahmer still directly owns 275,857 shares, including 9,153 shares underlying RSUs, indicating the sale was a small portion of his total holdings.
